Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
N SinghV L Yu

Abstract

The efficacy of low-dose fluconazole (200 mg orally administered thrice weekly) as primary prophylaxis for cryptococcal infection was prospectively assessed in a multicenter trial involving 218 patients who were infected with human immunodeficiency virus (HIV) and who had CD4 cell counts of < or = 100/mm3. The median CD4 cell count at baseline was 39/mm3, 58% of the patients had an AIDS-defining illness or infection prior to enrollment. Cryptococcal meningitis occurred in 0.4% (1) of the 218 patients. The breakthrough isolate was susceptible to fluconazole, and the fluconazole kinetic study demonstrated adequate drug absorption and serum fluconazole levels; noncompliance could not be excluded in this case. Mucocutaneous and/or esophageal candidiasis developed in 18% (40) of the patients. Noncompliance with fluconazole therapy was the only variable independently associated with breakthrough candidiasis in the study patients (P = .00002). Thus, fluconazole (200 mg thrice weekly) given to HIV-infected patients with CD4 cell counts of < or = 100/mm3 was efficacious as primary prophylaxis for cryptococcosis, with notably lower costs and increased convenience for patients in comparison with daily administration of the drug.

Citations

Nov 30, 2000·Current Infectious Disease Reports·W G Powderly
Aug 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M M McNeilD W Warnock
Dec 12, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Suwat ChariyalertsakKenrad E Nelson
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David B MeyaDavid R Boulware
Sep 3, 1999·The Journal of Antimicrobial Chemotherapy·V T Andriole
Nov 20, 1997·AIDS·N CarréA van den Hoek
Apr 16, 2002·AIDS·Neil FrenchCharles F Gilks
Sep 28, 2010·Tropical Medicine & International Health : TM & IH·Emmanuelle EspiéMar Pujades-Rodríguez
Jan 9, 1998·Infectious Disease Clinics of North America·A Espinel-Ingroff
May 12, 2015·Current Tropical Medicine Reports·David MeyaJoseph N Jarvis
Jan 16, 2007·Revista Do Instituto De Medicina Tropical De São Paulo·Sandra Lopes Mattos e DinatoNey Romiti
May 20, 1999·AIDS Research and Human Retroviruses·K A OurslerR E Chaisson
Aug 30, 2018·The Cochrane Database of Systematic Reviews·Ajibola A AwotiwonIngrid Eshun-Wilson
Dec 1, 2005·Expert Opinion on Pharmacotherapy·Laura Waters, Mark Nelson
Dec 30, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D V HavlirS A Bozzette
Jul 22, 2005·The Cochrane Database of Systematic Reviews·L W ChangG W Rutherford
Jul 1, 1997·Clinical Microbiology Reviews·O Lortholary, B Dupont
Oct 12, 2004·Biochemical and Biophysical Research Communications·S G RevankarB L Wickes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.